Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

1(33.3%)

Phase 4

1(33.3%)

N/A

1(33.3%)

3Total

Phase 1(1)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01061476Phase 1Completed

Sleep Apnea Treatment With Expiratory Resistance(Provent™)

Role: collaborator

NCT00849043Completed

Extension Study of Original Protocol AERO C009 for Obstructive Sleep Apnea-hypopnea

Role: lead

NCT00901771Not ApplicableCompleted

Study of Provent Treatment of Obstructive Sleep Apnea in Patients Who Are Non-compliant With CPAP

Role: collaborator

NCT00772044Phase 4Completed

Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea

Role: lead

All 4 trials loaded